Interstitial Lung Disease Exacerbations Study (INDEX)

Interstitial lung disease (ILD) is an umbrella term covering numerous conditions that affect the lung tissue, interfering with the ability of the lungs to take up oxygen. Most ILDs get worse gradually, but sometimes patients can experience a sudden worsening in their symptoms called an acute exacerbation (AE-ILD). Most studies in this area have been done in AEs of idiopathic pulmonary fibrosis (AE-IPF), as IPF is the commonest form of ILD. AE-IPF has very poor outcomes, however AEs of other ILDs are less well studied. Furthermore, there is currently no treatment guideline or established standard of care for the management of patients with AE-fILD.

The aim of this research project is to gain a better understanding of AE-ILD in a real-world population. By looking at the clinical records of patients with AE-ILD, the study aims to describe the patient population that gets AE-ILD and how these patients are treated in the "real world" setting. The study will also gather information on patient characteristics such as type of ILD and test results at the time of AE-ILD, and see if any of these factors are associated with better/ worse outcomes in AE-ILD. Finally, the study will collect data on the treatment approaches taken, including both medical therapy such as steroid treatment, as well as specialist care team input. This data on treatment will be used to identify associations between individual treatments and outcomes, as well as to evaluate the NHS services being provided to patients with AE-ILD.

Overall, this study will enhance understanding of AE-ILD. This study will provide information to help design clinical trials to test treatments for AE-ILD, to help us create evidence-based clinical guidelines for AE-ILD, and improve the management of patients with AE-ILD.

Study Overview

• Status: Active, not recruiting
• Conditions: Pulmonary Fibrosis; Interstitial Lung Disease (ILD)

Detailed Description

Idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (PF-ILDs) are increasingly common fatal disorders with a median life expectancy from diagnosis of 3-5 years. Fibrotic interstitial lung disease (fILD) is a general term for a group of conditions that involve scarring of the lung (fibrosis) with or without evidence of inflammation. While different ILDs are associated with different aetiological factors and disease courses, there is considerable overlap in the characteristics of these conditions. In general, fILDs usually progress in terms of symptoms, lung function, and radiological features, resulting in increasing symptoms and respiratory failure.

In addition to the gradual progression that is typical of fILD, these conditions can become acutely worse during episodes of acute exacerbation (AE-fILD). An AE can be defined as an acute (less than one month) deterioration in symptoms associated with new ground glass changes on CT chest and not explained by other pathology such as pulmonary embolus, pneumothorax, or cardiac failure (adapted from the definition by Collard et al for AE-IPF). The prognosis of acute exacerbations of idiopathic pulmonary fibrosis (IPF), the commonest form of fILD, is very poor (over 90% in-hospital mortality in some reports). However, there has been very little research on AEs in non-IPF fILD.

Furthermore, there is currently no treatment guideline or established standard of care for the management of patients with AE-fILD. Other significant gaps in the literature in this area, include:

• What is the typical clinical course and outcome of acute exacerbations in non-IPF fILD?
• What features predict the risk of in-hospital and post-discharge mortality from AE-fILD (e.g. age, sex, baseline diagnosis)?
• Are currently used treatments for AE-fILD effective? How should AE-fILD be managed (steroids, oxygen therapy etc)?
• How well are aspects of care that patients find important (e.g. provision of specialist palliative care, opportunities to discuss advanced care planning, and oxygen therapy) delivered to patients with AE-fILD?

There are significant gaps in the literature in the field of AE-fILD. Much of the current practice in AE-fILD management is based on clinical judgement, and adequately powered randomised controlled trials to identify appropriate treatment approaches have not been performed. This has led to significant heterogeneity in the approach to AE-fILD between clinicians and centres, an issue illustrated by the fact that only one of seven NHS trusts in the East Midlands has a treatment guideline specific for the management of AE-fILD (unpublished data). This lack of consistency in approach poses a significant challenge to the design of randomised control trials, as heterogeneity within a standard care control arm can obscure any specific signals. Furthermore, in the absence of RCTs, there is the potential that clinicians may unintentionally use interventions that are harmful.

The study is an observational cohort study of patients admitted to hospital with AE-fILD to answer the questions listed above. These data will help to clarify research priorities in this area, and identify areas where care could improve and allow us to make recommendations for clinical care. The study will also use these data to inform and generate hypotheses for future clinical trials.

• Study Type: Observational
• Enrollment (Estimated): 1500

Contacts and Locations

Study Locations

• United Kingdom
  • Bath, United Kingdom
    • Royal United Hospitals Bath NHS Foundation Trust
  • Bristol, United Kingdom
    • North Bristol NHS Trust
  • Exeter, United Kingdom
    • Royal Devon University Hospitals NHS Foundation Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with fibrotic interstitial lung disease admitted to hospital with exacerbation of pulmonary fibrosis as per inclusion and exclusion criteria

Description

Inclusion Criteria:

• Patients admitted to an acute NHS trust during study period 1st September 2022-31st August 2023 with an underlying or new diagnosis of an ILD (defined by ICD-10 codes in Table 1) with a fibrotic phenotype (established fibrosis on current or previous radiological imaging) AND
• Increasing pulmonary symptoms AND

• No extra-parenchymal cause identified as primary cause of admission

  • Segmental or larger pulmonary embolus as main discharge diagnosis in absence of acute exacerbation features on imaging
  • Pleural effusion as main discharge diagnosis
  • Pneumothorax as main discharge diagnosis in absence of acute exacerbation features on imaging
  • Left sided heart failure or volume overload

Exclusion Criteria

• No underlying or new diagnosis of ILD with a fibrotic phenotype
• Acute presentation of pneumonitis/ILD without evidence of fibrosis (Table 2)
• Non-respiratory related hospital admission (no increasing pulmonary symptoms)

• Respiratory related hospital admission due to extra-parenchymal cause

  • Segmental or larger pulmonary embolus as main discharge diagnosis in absence of acute exacerbation features on imaging
  • Pleural effusion as main discharge diagnosis
  • Pneumothorax as main discharge diagnosis in absence of acute exacerbation features on imaging
  • Left sided heart failure or volume overload
• Participant signatory to NHS National Data Opt Out
• Elective/non-emergency admission
• Admission under non-medical specialty
• In cases where there are >=1 eligible admissions only the first (index) admission shall be included

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients with exacerbation of fibrotic interstitial lung disease; Patients with exacerbation of fibrotic interstitial lung disease as per inclusion and exclusion criteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Transplant free survival	Transplant-free survival	90 days post date of hospital admission

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Transplant free survival	Transplant free survival	Date of discharge from hospital for index admission (Up to 24 hours), 30 days, 90 days (Primary endpoint), 6 months, 1 year
Pulmonary Function Testing	Change in forced vital capacity (FVC) from pre-admission values	6 months and 12 months from date of index admission
Pulmonary function testing	Change in diffusion capacity (DLCO) from pre-admission values	6 months and 12 months from date of index admission
Oxygen	Use of long term or ambulatory oxygen	At the point of discharge from index admission (up to 24 hours)

Collaborators and Investigators

• Sponsor: Royal Devon and Exeter NHS Foundation Trust
• Collaborators: Nottingham University Hospitals NHS Trust; University Hospitals, Leicester; Papworth Hospital NHS Foundation Trust; North Bristol NHS Trust
• Investigators: Principal Investigator: Michael Gibbons, MBChB, Royal Devon and University healthcare trust

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026

Study Registration Dates

• First Submitted: October 30, 2024
• First Submitted That Met QC Criteria: November 11, 2024
• First Posted (Actual): November 13, 2024

Study Record Updates

• Last Update Posted (Actual): May 18, 2025
• Last Update Submitted That Met QC Criteria: May 14, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Exacerbation; Interstitial lung disease
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Respiratory Tract Diseases; Fibrosis; Lung Diseases; Disease Progression; Pulmonary Fibrosis; Lung Diseases, Interstitial
• Other Study ID Numbers: 2501703

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: IPD will not be shared due to lack of informed consent.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No